{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(8)"],"submitter":["Kawamoto Y"],"funding":["Eli Lilly Japan K.K."],"pubmed_abstract":["<h4>Background</h4>Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer.<h4>Materials and methods</h4>Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m2 combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug.<h4>Result"],"journal":["The oncologist"],"pagination":["e642-e649"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9355819"],"repository":["biostudies-literature"],"pubmed_title":["Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603."],"pmcid":["PMC9355819"],"pubmed_authors":["Dazai M","Nakamura M","Komatsu Y","Sato A","Tsuji Y","Okada K","Sakamoto N","Sakata Y","Shindo Y","Meguro T","Yuki S","Harada K","Sogabe S","Sekiguchi M","Sawada K","Ishiguro A","Ito YM","Kawamoto Y","Okuda H","Muto O"],"additional_accession":[]},"is_claimable":false,"name":"Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.","description":"<h4>Background</h4>Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer.<h4>Materials and methods</h4>Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m2 combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug.<h4>Result","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-22T11:30:28.761Z","creation":"2025-04-05T23:57:28.872Z"},"accession":"S-EPMC9355819","cross_references":{"pubmed":["35579511"],"doi":["10.1093/oncolo/oyac086"]}}